首页> 外文期刊>The Journal of biological chemistry >The Oncogene Metadherin Modulates the Apoptotic Pathway Based on the Tumor Necrosis Factor Superfamily Member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in Breast Cancer
【24h】

The Oncogene Metadherin Modulates the Apoptotic Pathway Based on the Tumor Necrosis Factor Superfamily Member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in Breast Cancer

机译:基于肿瘤坏死因子超家族成员小径(肿瘤坏死因子相关凋亡诱导配体)在乳腺癌中调节癌胚型途径调节凋亡途径

获取原文
           

摘要

Metadherin (MTDH), the newly discovered gene, is overexpressed in more than 40% of breast cancers. Recent studies have revealed that MTDH favors an oncogenic course and chemoresistance. With a number of breast cancer cell lines and breast tumor samples, we found that the relative expression of MTDH correlated with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity in breast cancer. In this study, we found that knockdown of endogenous MTDH cells sensitized the MDA-MB-231 cells to TRAIL-induced apoptosis both in vitro and in vivo. Conversely, stable overexpression of MTDH in MCF-7 cells enhanced cell survival with TRAIL treatment. Mechanically, MTDH down-regulated caspase-8, decreased caspase-8 recruitment into the TRAIL death-inducing signaling complex, decreased caspase-3 and poly(ADP-ribose) polymerase-2 processing, increased Bcl-2 expression, and stimulated TRAIL-induced Akt phosphorylation, without altering death receptor status. In MDA-MB-231 breast cancer cells, sensitization to TRAIL upon MTDH down-regulation was inhibited by the caspase inhibitor Z-VAD-fmk (benzyloxycarbonyl-VAD-fluoromethyl ketone), suggesting that MTDH depletion stimulates activation of caspases. In MCF-7 breast cancer cells, resistance to TRAIL upon MTDH overexpression was abrogated by depletion of Bcl-2, suggesting that MTDH-induced Bcl-2 expression contributes to TRAIL resistance. We further confirmed that MTDH may control Bcl-2 expression partly by suppressing miR-16. Collectively, our results point to a protective function of MTDH against TRAIL-induced death, whereby it inhibits the intrinsic apoptosis pathway through miR-16-mediated Bcl-2 up-regulation and the extrinsic apoptosis pathway through caspase-8 down-regulation.
机译:Metadherin(MTDH)是新发现的基因,在超过40%的乳腺癌中过表达。最近的研究表明,MTDH有利于致癌过程和化学性。随着许多乳腺癌细胞系和乳腺肿瘤样品,我们发现MTDH的相对表达与乳腺癌中肿瘤坏死因子相关凋亡诱导配体(TRAIL)敏感性相关。在这项研究中,我们发现内源性MTDH细胞的敲低敏化了MDA-MB-231细胞,以在体外和体内诱导凋亡。相反,MCF-7细胞中MTDH的稳定过表达增强了通过TRAIL治疗的细胞生存。机械,MTDH下调的Caspase-8,降低Caspase-8募集到痕量的死亡诱导信号络合物,降低的Caspase-3和聚(ADP-核糖)聚合酶-2加工,增加Bcl-2表达和刺激的尾部 - 诱导AKT磷酸化,不改变死亡受体状态。在MDA-MB-231乳腺癌细胞中,通过Caspase抑制剂Z-VAD-FMK(苄氧基羰基 - Vad-氟甲基酮)抑制了对MTDH下调的敏化抑制,表明MTDH耗竭刺激了胱天蛋白酶的活化。在MCF-7乳腺癌细胞中,通过耗尽Bcl-2,在MTDH过表达时抗迹线的抗性,表明MTDH诱导的Bcl-2表达有助于耐污染。我们进一步证实,MTDH可以通过抑制miR-16部分地控制Bcl-2表达。统称,我们的结果指出了MTDH对痕迹诱导的死亡的保护功能,从而通过MiR-16介导的Bcl-2上调和通过Caspase-8下调来抑制内在凋亡途径和外部凋亡途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号